SELL and neoplasm: Several studies have shown that in the case of patient-derived peripheral blood, initial selection of PD-1+ and/or antigenic experience (CD45RO+CD62L+, CD45RO+CD62L− or CD45RO−CD62L−) T cells can further enhance tumor-specific T-cell enrichment in vitro [203, 204].